Cited by 1,147Multiple Myeloma Research and TreatmentsBone health and treatmentsProtein Degradation and Inhibitors

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Open access

McCarthy, Philip L., Owzar, Kouros, Hofmeister, Craig C., Hurd, David D., Hassoun, Hani, Richardson, Paul G., Giralt, Sergio, Stadtmauer, Edward A., Weisdorf, Daniel J., Vij, Ravi, Moreb, Jan S., Callander, Natalie Scott, Van Besien, Koen, Gentile, Teresa, Isola, Luis, Maziarz, Richard T., Gabriel, Don A., Bashey, Asad, Landau, Heather, Martin, Thomas, Qazilbash, Muzaffar H., Levitan, Denise, McClune, Brian, Schlossman, Robert, Hars, Vera, Postiglione, John, Jiang, Chen, Bennett, Elizabeth, Barry, Susan, Bressler, Linda, Kelly, Michael, Seiler, Michele, Rosenbaum, Cara, Hari, Parameswaran, Pasquini, Marcelo C., Horowitz, Mary M., Shea, Thomas C., Devine, Steven M., Anderson, Kenneth C., Linker, Charles·2012·New England Journal of Medicine

DOI 10.1056/nejmoa1114083PMC PMC3744390

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. METHODS: Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15). RESULTS: The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding, 20% of patients who received lenalidomide and 44% of patients who received placebo had progressive disease or had died (P<0.001); of the remaining 128 patients who received placebo and who did not have progressive disease, 86 crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%) had disease progression or had died. The median time to progression was 46 months in the lenalidomide group and 27 months in the placebo group (P<0.001). A total of 35 patients who received lenalidomide (15%) and 53 patients who received placebo (23%) died (P=0.03). More grade 3 or 4 hematologic adverse events and grade 3 nonhematologic adverse events occurred in patients who received lenalidomide (P<0.001 for both comparisons). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%). CONCLUSIONS: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00114101.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1114083

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Analysis of Survival Data
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,269
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citation
Multiple Myeloma
Palumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Self-citation
The Statistical Analysis of Failure Time Data
Klein, J. P., Kalbfleisch, J. D., & Prentice, R. L. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,248
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Multiple myeloma
Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164
Self-citation

Flagged first, then by citations

Show all 42 references

Research works printed but not linked: 2

10.1001/archinte.135.1.147 · DOI
10.2307/2281868 · DOI · Paper page

Sorted by citations

Items 201–300 of 1,000

Characteristics and Outcomes of Patients With Multiple Myeloma Who Develop Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
Pemmaraju, N., Shah, D., Kantarjian, H. M., Orlowski, R. Z., Nogueras‐González, G. M., Baladandayuthapani, V., Jain, N., Wagner, V., Garcia‐Manero, G., Shah, J. J., et al. (2014) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2014.07.001 · Cited by 47
Self-citation
IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM)
Krönke, J., Kuchenbauer, F., Kull, M., Teleanu, V, Bullinger, L., Bunjes, D., Greiner, A., Kolmus, S., Köpff, S., Schreder, M., et al. (2017) · Leukemia · doi:10.1038/leu.2016.384 · Cited by 46
Enhanced lysosomal escape of cell penetrating peptide-functionalized metal–organic frameworks for co-delivery of survivin siRNA and oridonin
Cai, M., Yao, Y., Yin, D., Zhu, R., Fu, T., Kong, J., Wang, K., Liu, J., Yao, A., Ruan, Y., et al. (2023) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2023.04.126 · Cited by 45
Immunomodulatory drugs in multiple myeloma
Andhavarapu, S., & Roy, V. (2013) · Expert Review of Hematology · doi:10.1586/ehm.12.62 · Cited by 47
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
Dimopoulos, M. A., Wang, M. L., Maisnar, V., Minařík, J., Bensinger, W., Mateos, M., Obreja, M., Blædel, J., & Moreau, P. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0583-7 · Cited by 46
Immunotherapy in Multiple Myeloma
Soekojo, C. Y., Ooi, M. G. M., Mel, S. D., & Chng, W. J. (2020) · Cells · doi:10.3390/cells9030601 · Cited by 48
CARs in the Lead Against Multiple Myeloma
Ormhøj, M., Bedoya, F., Frigault, M. J., & Maus, M. V. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0373-2 · Cited by 47
Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry
Abonour, R., Wagner, L. I., Durie, B. G. M., Jagannath, S., Narang, M., Terebelo, H. R., Gasparetto, C., TOOMEY, K. E., Hardin, J. W., Kitali, A., et al. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3446-y · Cited by 45
Second Primary Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
Krishnan, A. Y., Mei, M. G., Sun, C., Thomas, S. H., Teh, J. B., Kang, T., Htut, M., Somlo, G., Sahebi, F., Forman, S. J., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.09.023 · Cited by 45
Minimal Residual Disease in Multiple Myeloma
Munshi, N. C., & Anderson, K. C. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2124 · Cited by 45
Self-citation
Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation
Kazmi, S. M. A., Nusrat, M., Gunaydin, H., Cornelison, A. M., Shah, N. D., Kebriaei, P., Nieto, Y. L., Parmar, S., Popat, U., Oran, B., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.07.641 · Cited by 44
Self-citation
Heterogeneous cobalt catalysts for reductive amination with H 2 : general synthesis of secondary and tertiary amines
Mao, F., Sui, D., Qi, Z., Fan, H., Chen, R., & Huang, J. (2016) · RSC Advances · doi:10.1039/c6ra21415k · Cited by 44
How I treat the young patient with multiple myeloma
Gandolfi, S., Prada, C. P., & Richardson, P. G. G. (2018) · Blood · doi:10.1182/blood-2017-05-693606 · Cited by 47
Self-citation
Role of Stem Cell Transplantation in Multiple Myeloma
Devarakonda, S. S., Efebera, Y. A., & Sharma, N. (2021) · Cancers · doi:10.3390/cancers13040863 · Cited by 46
Recent advances in hematopoietic stem cell transplantation
Norkin, M. N., & Wingard, J. R. (2017) · F1000Research · doi:10.12688/f1000research.11233.1 · Cited by 43
Targeting the Microenvironment for Treating Multiple Myeloma
Neumeister, P., Schulz, E., Pansy, K., Szmyra, M., & Deutsch, A. J. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147627 · Cited by 43
Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma
Usmani, S. Z., Sawyer, J. R., Rosenthal, A., Cottler‐Fox, M., Epstein, J., Yaccoby, S., Sexton, R., Hoering, A., Singh, Z. N., Heuck, C. J., et al. (2013) · Blood · doi:10.1182/blood-2012-11-466961 · Cited by 42
Multiple myeloma—translation of trial results into reality
Moreau, P., & Rajkumar, S. V. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30954-0 · Cited by 42
Single-Tube 10-Fluorochrome Analysis for Efficient Flow Cytometric Evaluation of Minimal Residual Disease in Plasma Cell Myeloma
Royston, D. J., Gao, Q., Nguyen, N., Maslak, P. G., Doǧan, A., & Roshal, M. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw052 · Cited by 43
Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma
Stecco, A., Buemi, F., Iannessi, A., Carriero, A., & Gallamini, A. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1434881 · Cited by 42
Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis
Zhang, S., Kulkarni, A. A., Xu, B., Chu, H., Kourelis, T., Go, R. S., Wang, M. L., Bachanová, V., & Wang, Y. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0298-1 · Cited by 42
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma
Sonneveld, P., Dimopoulos, M. A., Beksac, M., van der Holt, B., Aquino, S., Ludwig, H., Zweegman, S., Zander, T., Zamagni, E., Wester, R., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01045 · Cited by 43
Better therapy requires better response evaluation: Paving the way for minimal residual disease testing for every myeloma patient
Landgren, O., & Owen, R. G. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21273 · Cited by 44
Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis
Scott, E. C., Hari, P., Sharma, M. R., Le‐Rademacher, J. G., Huang, J., Vogl, D. T., Abidi, M. H., Beitinjaneh, A., Fung, H. C. H., Ganguly, S., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.07.007 · Cited by 41
Self-citation
Health-related quality of life results from the IFM 2009 trial: treatment with lenalidomide, bortezomib, and dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma
Roussel, M., Hébraud, B., Hulin, C., Perrot, A., Caillot, D., Stoppa, A., Macro, M., Escoffre‐Barbe, M., Arnulf, B., Belhadj, K., et al. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1719091 · Cited by 41
Venous thromboembolism in hematopoietic stem cell transplant recipients
Chaturvedi, S., Neff, A. T., Nagler, A., Savani, U. B., Mohty, M., & Savani, B. N. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.308 · Cited by 40
Acute Kidney Allograft Rejection Precipitated by Lenalidomide Treatment for Multiple Myeloma
Lum, E. L., Huang, E., Bunnapradist, S., Pham, T. N., & Danovitch, G. M. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.11.024 · Cited by 40
Anti-VEGF Drugs in the Treatment of Multiple Myeloma Patients
Ria, R., Melaccio, A., Racanelli, V., & Vacca, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061765 · Cited by 40
Genome Instability in Multiple Myeloma: Facts and Factors
Aksenova, A. Y., Zhuk, A. S., Lada, A. G., Zotova, I. V., Stepchenkova, E. I., Kostroma, I. I., Gritsaev, S. V., & Pavlov, Y. I. (2021) · Cancers · doi:10.3390/cancers13235949 · Cited by 43
VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT
Terpos, E., Christoulas, D., Kastritis, E., Ρούσσου, Μ., Migkou, M., Eleutherakis‐Papaiakovou, E., Gavriatopoulou, M., Gkotzamanidou, M. A., Kanellias, N., Manios, E. D., et al. (2013) · Leukemia · doi:10.1038/leu.2013.267 · Cited by 39
Novel Agents for Multiple Myeloma to Overcome Resistance in Phase III Clinical Trials
Orlowski, R. Z. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.07.007 · Cited by 39
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma
Rossi, A., Mark, T. M., Jayabalan, D. S., Christos, P. J., Zafar, F., Pekle, K. A., Pearse, R. N., Chen‐Kiang, S., Coleman, M., & Niesvizky, R. (2013) · Blood · doi:10.1182/blood-2012-08-448563 · Cited by 39
Emerging Stem Cell Therapies: Treatment, Safety, and Biology
Sng, J., & Lufkin, T. (2012) · Stem Cells International · doi:10.1155/2012/521343 · Cited by 40
Integration of Novel Agents into the Care of Patients with Multiple Myeloma
Orlowski, R. Z., & Lonial, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0861 · Cited by 39
Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation
Uy, G. L., Costa, L. J., Hari, P., Zhang, M.-J., Huang, J.-X., Anderson, K. C., Bredeson, C., Callander, N. S., Cornell, R. F., Perez, M. A. D., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.190 · Cited by 39
Self-citation
The evolution of stem-cell transplantation in multiple myeloma
Mahajan, S., Tandon, N., & Kumar, S. K. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718761776 · Cited by 40
Lenalidomide for the treatment of relapsed and refractory multiple myeloma
Görgün, G., van de Donk, N. W. C. J., Groen, R. W. J., Jakubı́ková, J., Mitsiades, C. S., Hideshima, T., Richardson, P. G. G., Nijhof, Raymakers, Lokhorst, H. M., et al. (2012) · Cancer Management and Research · doi:10.2147/cmar.s27087 · Cited by 38
Self-citation
Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation
Takamatsu, H. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6100091 · Cited by 40
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma
Alonso, R., Cedena, M., Wong, S. W. K., Shah, N. D., Ríos, R., Moraleda, J. M., López‐Jiménez, J., García, C., Bahri, N., Valeri, A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001508 · Cited by 38
Self-citation
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma
Dhakal, B., Shah, N. D., Kansagra, A. J., Kumar, A., Lonial, S., Garfall, A. L., Cowan, A. J., Poudyal, B. S., Costello, C. L., Gay, F., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.03.019 · Cited by 40
Self-citation
Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis
Ragon, B. K., Shah, M. V., D’Souza, A., Estrada‐Merly, N., Gowda, L., George, G., Lima, M. J. G. D., Hashmi, S. K., Kharfan‐Dabaja, M. A., Majhail, N. S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009138 · Cited by 38
Self-citation
Single-dose pharmacokinetics of lenalidomide in healthy volunteers: dose proportionality, food effect, and racial sensitivity
Chen, N., Kasserra, C., Reyes, J. F., Liu, L., & Lau, H. S. H. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1966-z · Cited by 38
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma
Arikian, S. R., Milentijevic, D., Binder, G., Gibson, C. J., Hu, X., Nagarwala, Y. M., Hussein, M. A., Corvino, F. A., Surinach, A., & Usmani, S. Z. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1031732 · Cited by 37
Doublets, triplets, or quadruplets of novel agents in newly diagnosed myeloma?
Rajkumar, S. V. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.354.3798330 · Cited by 37
Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM
Jagannath, S., Abonour, R., Durie, B. G. M., Narang, M., Terebelo, H. R., Gasparetto, C., TOOMEY, K. E., Hardin, J. W., Wagner, L. I., Agarwal, A., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018017186 · Cited by 37
Staging and prognostication of multiple myeloma
Fonseca, R., Monge, J., & Dimopoulos, M. A. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.882224 · Cited by 39
Back to the Future! The Evolving Role of Maintenance Therapy after Hematopoietic Stem Cell Transplantation
Hourigan, C. S., McCarthy, P. L., & Lima, M. J. G. D. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.11.017 · Cited by 36
Self-citation
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
Khouri, I. F., Curbelo, I. F., Turturro, F., Jabbour, E. J., Milton, D. R., Bassett, R. L., Vence, L. M., Allison, J. P., Gulbis, A. M., & Sharma, P. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2777 · Cited by 36
Tandem Autologous-Autologous versus Autologous-Allogeneic Hematopoietic Stem Cell Transplant for Patients with Multiple Myeloma: Long-Term Follow-Up Results from the Blood and Marrow Transplant Clinical Trials Network 0102 Trial
Giralt, S., Costa, L. J., Maloney, D. G., Krishnan, A. Y., Fei, M., Antin, J. H., Brunstein, C. G., Geller, N. L., Goodman, S. A., Hari, P., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.11.018 · Cited by 36
Self-citation
Lenalidomide before and after autologous stem cell transplantation for transplant-eligible patients of all ages in the randomized, phase III, Myeloma XI trial
Jackson, G. H., Davies, F. E., Pawlyn, C., Cairns, D. A., Striha, A., Collett, C., Waterhouse, A., Jones, J. R., Kishore, B., Garg, M. K., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.247130 · Cited by 36
Lenalidomide and secondary acute lymphoblastic leukemia: a case series
Tan, M., Fong, R., Lo, M., & Young, R. (2015) · Hematological Oncology · doi:10.1002/hon.2248 · Cited by 35
Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma
Wang, X. S., Shi, Q., Williams, L. A., Shah, N. D., Mendoza, T. R., Cohen, E. N., Reuben, J. M., Cleeland, C. S., & Orlowski, R. Z. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.956313 · Cited by 35
Daratumumab, Elotuzumab, and the Development of Therapeutic Monoclonal Antibodies in Multiple Myeloma
Laubach, J. P., Prada, C. P., Richardson, P. G. G., & Longo, D. (2016) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.550 · Cited by 36
Self-citation
Posttransplant maintenance therapy in multiple myeloma: the changing landscape
Sengsayadeth, S. M., Malard, F., Savani, B. N., Garderet, L., & Mohty, M. (2017) · Blood Cancer Journal · doi:10.1038/bcj.2017.23 · Cited by 35
Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis
Varma, A., Sui, D., Milton, D. R., Tang, G., Saini, N., Hasan, O., Mukherjee, A., Joseph, J. J., Bashir, Q., Rondón, G., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.12.726 · Cited by 35
Self-citation
Multiple myeloma
Менделеева, Л. П., Votyakova, O. M., Rekhtina, I. G., Osmanov, E. A., Poddubnaya, I. V., Гривцова, Л. Ю., Falaleeva, N. A., Байков, В. В., Kovrigina, A. M., Nevol’skikh, A. A., et al. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2020.4.200457 · Cited by 36
Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study
Martino, M. V., Montanari, M., Ferrara, F., Ciceri, F., Scortechini, I., Palmieri, S., Marktel, S., Cimminiello, M., Messina, G., Irrera, G., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.03.027 · Cited by 36
Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma
Sivaraj, D., Green, M. M., Li, Z., Sung, A. D., Sarantopoulos, S., Kang, Y., Long, G. D., Horwitz, M. E., Lopez, R. D., Sullivan, K. M., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.11.010 · Cited by 35
Lenalidomide in Myeloma — A High-Maintenance Friend
Badros, A. Z. (2012) · New England Journal of Medicine · doi:10.1056/nejme1202819 · Cited by 35
Novel agents and new therapeutic approaches for treatment of multiple myeloma
Ria, R. (2014) · World Journal of Methodology · doi:10.5662/wjm.v4.i2.73 · Cited by 36
Can we deconstruct cancer, one patient at a time?
Blau, C. A., & Liakopoulou, E. (2012) · Trends in Genetics · doi:10.1016/j.tig.2012.09.004 · Cited by 34
Multiple myeloma maintenance therapy: A review of the pharmacologic treatment
Shank, B. R., Brown, V. T., & Schwartz, R. N. (2014) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155213514468 · Cited by 36
Current Therapeutic Strategy for Multiple Myeloma
Suzuki, K. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hys215 · Cited by 34
Optimizing current and emerging therapies in multiple myeloma: a guide for the hematologist
Raza, S., Safyan, R. A., E, E. R. P., Bowman, C. A., & Lentzsch, S. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716680548 · Cited by 34
Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation
Chakraborty, R., Muchtar, E., Kumar, S. K., Buadi, F. K., Dingli, D., Dispenzieri, A. A., Hayman, S. R., Hogan, W. J., Kapoor, P., Lacy, M. Q., et al. (2017) · Leukemia · doi:10.1038/leu.2017.256 · Cited by 34
Lenalidomide versus bortezomib maintenance after frontline autologous stem cell transplantation for multiple myeloma
Baertsch, M., Mai, E. K., Hielscher, T., Bertsch, U., Salwender, H. J., Munder, M., Fuhrmann, S., Dührsen, U., Brossart, P., Neben, K., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00390-3 · Cited by 35
Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation
Bock, F. M., Lu, G. G., Srour, S. A., Gaballa, S. R., Lin, H. Y., Baladandayuthapani, V., Honhar, M., Stich, M., Shah, N. D., Bashir, Q., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.09.003 · Cited by 34
Self-citation
Update on second primary malignancies in multiple myeloma: a focused review
Landgren, O., & Mailankody, S. (2014) · Leukemia · doi:10.1038/leu.2014.22 · Cited by 33
Long-term outcome with lenalidomide and dexamethasone therapy for newly diagnosed multiple myeloma
Srivastava, G., Rana, V., Lacy, M. Q., Buadi, F. K., Hayman, S. R., Dispenzieri, A. A., Gertz, M. A., Dingli, D., Zeldenrust, S. R., Russell, S. J., et al. (2013) · Leukemia · doi:10.1038/leu.2013.143 · Cited by 33
Have drug combinations supplanted stem cell transplantation in myeloma?
Palumbo, A. P., & Cavallo, F. (2012) · Blood · doi:10.1182/blood-2012-05-423202 · Cited by 33
Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial
Straka, C., Liebisch, P., Salwender, H. J., Hennemann, B., Metzner, B., Knop, S. T., Adler-Reichel, S., Gerecke, C., Wandt, H., Bentz, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.151860 · Cited by 36
The role of maintenance therapy in multiple myeloma
Lipe, B. C., Vukas, R. R., & Mikhael, J. R. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.89 · Cited by 34
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
Chung, D. J., Shah, N. D., Wu, J., Logan, B. R., Bisharat, L., Callander, N. S., Cheloni, G., Anderson, K. C., Chodon, T., Dhakal, B., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0235 · Cited by 33
Self-citation
Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?
Richardson, P. G. G., Laubach, J. P., Munshi, N. C., & Anderson, K. C. (2014) · Hematology · doi:10.1182/asheducation-2014.1.255 · Cited by 33
Self-citation
A phase II, single-arm, prospective study of bendamustine plus melphalan conditioning for second autologous stem cell transplantation in de novo multiple myeloma patients through a tandem transplant strategy
Martino, M. V., Tripepi, G. L., Messina, G., Vincelli, I. D., Console, G., Recchia, A. G., Gentile, M., Molica, S., & Morabito, F. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.94 · Cited by 32
Second primary malignancy after multiple myeloma‐population trends and cause‐specific mortality
Costa, L. J., Godby, K. N., Chhabra, S., Cornell, R. F., Hari, P., & Bhatia, S. (2018) · British Journal of Haematology · doi:10.1111/bjh.15426 · Cited by 32
Self-citation
Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma
Maffini, E., Storer, B. E., Sandmaier, B. M., Bruno, B., Sahebi, F., Shizuru, J. A., Chauncey, T. R., Hari, P., Lange, T., Pulsipher, M. A., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.200253 · Cited by 33
Self-citation
The Role of Salvage Second Autologous Hematopoietic Cell Transplantation in Relapsed Multiple Myeloma
Hagen, P. A., & Stiff, P. J. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.002 · Cited by 32
The role of high‐dose melphalan with autologous stem‐cell transplant in multiple myeloma: is it time for a paradigm shift?
Kazandjian, D. G., Mo, C. C., Landgren, O., & Richardson, P. G. G. (2020) · British Journal of Haematology · doi:10.1111/bjh.16764 · Cited by 35
Self-citation
Mathematical modeling for novel cancer drug discovery and development
Zhang, P., & Brusić, V. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.941351 · Cited by 32
General Reductive Amination of Aldehydes and Ketones with Amines and Nitroaromatics under H2 by Recyclable Iridium Catalysts
Sui, D., Mao, F., Fan, H., Qi, Z., & Huang, J. (2017) · Chinese Journal of Chemistry · doi:10.1002/cjoc.201600903 · Cited by 32
Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma
Lee, M. J., Wickner, P., Fanning, L., Schlossman, R., Richardson, P., Laubach, J., & Castells, M. (2014) · British Journal of Haematology · doi:10.1111/bjh.12925 · Cited by 31
Self-citation
Consolidation and maintenance therapy for multiple myeloma after autologous transplantation: where do we stand?
Mohty, M., Richardson, P. G. G., McCarthy, P. L., & Attal, M. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.83 · Cited by 31
Self-citation
Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of “progression-free survival 2” as a clinical trial end-point
Dimopoulos, M. A., Petrucci, M. T., Foà, R., Catalano, J., Kropff, M. H., Terpos, E., Zhang, J., Grote, L., Jacques, C. J., & Palumbo, A. (2015) · Haematologica · doi:10.3324/haematol.2014.120790 · Cited by 31
Second Autologous Stem Cell Transplant: An Effective Therapy for Relapsed Multiple Myeloma
Abbi, K. K. S., Zheng, J., Devlin, S. M., Giralt, S., & Landau, H. J. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.11.677 · Cited by 31
Self-citation
Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019
Mohyuddin, G. R., Koehn, K., Shune, L. O., Aziz, M., Abdallah, A.-O. A., McClune, B. L., Ganguly, S., McGuirk, J. P., & Kambhampati, S. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1867725 · Cited by 31
Self-citation
Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy
Cowan, A. J., Stevenson, P. A., Libby, E. N., Becker, P. S., Coffey, D. G., Green, D. J., Hyun, T. S., Fromm, J. R., Gopal, A. K., & Holmberg, L. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.02.017 · Cited by 31
Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma
Aggarwal, M., Agrawal, N., Yadav, N., Verma, P., Ahmed, R., Mehta, P., Kapoor, J., & Bhurani, D. (2018) · Annals of Hematology · doi:10.1007/s00277-018-3370-1 · Cited by 31
Expanding role of lenalidomide in hematologic malignancies
Ghosh, N., Grunwald, M. R., Fasan, O. O., & Bhutani, M. (2015) · Cancer Management and Research · doi:10.2147/cmar.s81310 · Cited by 30
Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients
McCarthy, P. L., & Hahn, T. (2013) · Hematology · doi:10.1182/asheducation-2013.1.496 · Cited by 31
Self-citation
The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma
Brayer, J. B., & Baz, R. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717710171 · Cited by 30
A Phase 2 Study of Pembrolizumab during Lymphodepletion after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
D’Souza, A., Hari, P., Pasquini, M. C., Braun, T., Johnson, B., Lundy, S. K., Couriel, D. R., Hamadani, M., Magenau, J. M., Dhakal, B., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.04.005 · Cited by 30
Self-citation
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
Salwender, H. J., Bertsch, U., Weisel, K. C., Dürig, J., Kunz, C., Benner, A., Blau, I. W., Raab, M. S., Hillengaß, J., Hose, D., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5600-x · Cited by 31
Immunomodulatory drugs in the treatment of multiple myeloma
Abe, Y., & Ishida, T. (2019) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyz083 · Cited by 30
How I treat frontline transplantation-eligible multiple myeloma
Perrot, A. (2021) · Blood · doi:10.1182/blood.2020008735 · Cited by 30
Beyond Clinical Trials in Patients With Multiple Myeloma: A Critical Review of Real-World Results
Bertamini, L., Bertuglia, G., & Oliva, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.844779 · Cited by 31
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
Terragna, C., Remondini, D., Martello, M., Zamagni, E., Pantani, L., Patriarca, F. F., Pezzi, A., Levi, G., Offidani, M., Proserpio, I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5718 · Cited by 31
Secondary malignancies in patients with multiple myeloma, Waldenström macroglobulinemia and monoclonal gammopathy of undetermined significance
Castillo, J. J., & Gertz, M. A. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1217527 · Cited by 30
Secondary primary malignancies during the lenalidomide–dexamethasone regimen in relapsed/refractory multiple myeloma patients
Kotchetkov, R., Masih‐Khan, E., Chu, C., Atenafu, E. G., Chen, C. I., Kukreti, V., Trudel, S., Tiedemann, R. E., & Reece, D. E. (2016) · Cancer Medicine · doi:10.1002/cam4.799 · Cited by 30
Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond
Guirguis, A. A., & Ebert, B. L. (2015) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2015.10.004 · Cited by 30

Authors: McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. S., Van Besien, K., Gentile, T., Isola, L., Maziarz, R. T., Gabriel, D. A., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Anderson, K. C., & Linker, C.
Affiliations: Roswell Park Comprehensive Cancer Center (US)
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
Duke University (US)
Memorial Sloan Kettering Cancer Center (US)
Dana-Farber Cancer Institute (US)
Abramson Cancer Center (US)
University of Minnesota Medical Center (US)
Washington University in St. Louis (US)
University of Florida (US)
University of Wisconsin–Madison (US)
State University of New York (US)
Mount Sinai Hospital (US)
Oregon Health & Science University (US)
University of North Carolina at Chapel Hill (US)
BMT Group (United States) (US)
University of California, San Francisco (US)
The University of Texas MD Anderson Cancer Center (US)
University of Chicago (US)
University of Chicago Medical Center (US)
Medical College of Wisconsin (US)
ORCID: McCarthy, Philip L.
Owzar, Kouros
Hofmeister, Craig C.
Hassoun, Hani
Richardson, Paul G.
Giralt, Sergio
Stadtmauer, Edward A.
Weisdorf, Daniel J.
Vij, Ravi
Moreb, Jan S.
Callander, Natalie Scott
Gentile, Teresa
Isola, Luis
Maziarz, Richard T.
Landau, Heather
Martin, Thomas
Qazilbash, Muzaffar H.
McClune, Brian
Jiang, Chen
Bennett, Elizabeth
Kelly, Michael
Rosenbaum, Cara
Hari, Parameswaran
Pasquini, Marcelo C.
Horowitz, Mary M.
Devine, Steven M.
Anderson, Kenneth C.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2012-05-10
Volume: 366
Issue: 19
Pages: 1770-1781
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1114083
PMC: PMC3744390
OpenAlex: W2125721471
Semantic Scholar: b20a8f57aae32a45c1804976b107b4ba1609688f
Cited by: 1,147
References: 42
Citations by year: 2026: 28 · 2025: 30 · 2024: 40 · 2023: 40 · 2022: 51 · 2021: 74 · 2020: 81 · 2019: 70 · 2018: 82 · 2017: 104 · 2016: 107 · 2015: 100 · 2014: 113 · 2013: 144 · 2012: 81
FWCI: 93.26
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
Funders: National Heart, Lung, and Blood Institute (U10HL069334, U10HL069301, U10HL069348, U10HL109526, U01HL069294, U10HL069294, U10HL069330, U10HL069315, U10HL069290, U10HL069286, UG1HL069286, UG1HL069315)
National Cancer Institute (U10CA033601, P50CA100707, U10CA031946, U10CA021115, U24CA076518)
Topics: Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
Health Sciences › Medicine › Oncology › Bone health and treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
Keywords: lenalidomide, multiple myeloma, autologous stem cell transplantation, maintenance therapy, time to progression, overall survival, secondary malignancies, hematologic adverse events, drug toxicity
MeSH terms: Lenalidomide, Adult, Aged, Antineoplastic Agents, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Neoplasms, Second Primary, Disease-Free Survival, Stem Cell Transplantation, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks